Business Wire

Alibaba Cloud Joins Technology Committee of the Content Delivery and Security Association (CDSA)

Share

Alibaba Cloud, the data intelligence backbone of Alibaba Group, has today announced its latest elected membership to the Content Delivery and Security Association (CDSA) Technology Committee, recognizing the importance of its robust, secure and scalable cloud platform currently used by many global media and entertainment (M&E) organisations.

Alibaba Cloud is the first China-based global cloud service provider to be elected to the Committee, which named 17 members to the committee for the annual term. The Committee, composed of industry leaders in the service provider community, will advise CDSA’s Board and Content Advisors on the new control framework and business model for application and cloud security assessments, new technology solutions and improved workflows for IP protection, security and compliance, that are reshaping the way content is produced, managed and delivered.

Alibaba Cloud is also a new member of CDSA and the Media & Entertainment Service Alliance (MESA). As the first Chinese company to become a member of MESA, the global leading cloud provider will work with the 150+ member companies to drive efficiencies, and help enable digital transformation of the M&E industry.

One of six technology communities within MESA, CDSA supports cybersecurity and content protection solutions within the M&E industry, including those responsible for film, television, games, music, and entertainment.

Guy Finley, President at MESA and CDSA, said, “We welcome Alibaba Cloud as a new member of CDSA’s Technology Committee, as Alibaba Cloud has demonstrated it embraces a collaborative approach along with their robust abilities in securing content for the entertainment industry. We look forward to working with these industry experts to drive new initiatives and broader global engagement with content owners around content protection and information security technology solutions for media and entertainment.”

Larry Xiao, General Manager of Security at Alibaba Cloud Intelligence and Vice President of Alibaba Group, said, “As the media and entertainment industry becomes primarily digital, cloud is playing an increasingly important role, and security is a critical consideration. Becoming a member of CDSA demonstrates our commitment to content security in the cloud, and we are pleased to be able to play our part in establishing security standards, setting industry best practices, and serving content providers, platform providers and customers. We also feel that working as part of the organisation will help increase transparency and collaboration between different companies in every part of the world.”

A number of renowned production studios - including Animal Logic and Territory Studio – have partnered with Alibaba Cloud, assured by its ability to meet dynamic production needs. They are using a range of cloud technologies to drive efficiencies in media production, from improving the speed of decision making through to easier cross-site collaboration with artists and developer teams across the world.

These latest memberships follow Alibaba Cloud being assessed by the Trusted Partner Network (TPN) earlier this year.

Alibaba Cloud provides a number of solutions that are used by entertainment customers to gain efficiencies in scale, reliability, global reach and security across their whole media supply chain. Whether for content creation, processing or distribution requirements, services like Object Storage Service, Express Connect, Cloud Storage Gateway, Media Processing Service and CDN (Content Delivery Network), enable customers to implement a full content supply chain more quickly without an upfront investment in infrastructure.

Alibaba Group’s rich and diverse ecosystem, including the digital media and entertainment business, provides various business scenarios to keep enhancing Alibaba Cloud’s technologies and algorithms, which will ultimately be turned into offerings to benefit a wide spectrum of customers.

“As part of the Alibaba ecosystem and global strategy, Alibaba Entertainment has a comprehensive quality content and new infrastructure, driving the industry digitalization and providing better entertainment experiences to audiences,” said Gao Xiaosong, Chairman of Alibaba Entertainment Strategic Committee. “We are very pleased to be able to push forward this significant long-term partnership. With the support of the Alibaba Ecosystem, such as cloud service, mobile payment, online ticketing, etc., we hope to contribute to the infrastructure of the global entertainment industry.”

For CDSA’s announcement on this latest membership, please visit: https://www.mesalliance.org/2020/04/08/cdsa-board-elects-new-members-to-tech-committee/

About Alibaba Cloud

Established in 2009, Alibaba Cloud (www.alibabacloud.com), the cloud computing and data intelligence arm of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner, and the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and government organisations. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.

Contact information

Luica Mak
Alibaba Group
+44 790 547 1332
luica@alibaba-inc.com

Xiaoyi Shao
Alibaba Group
+8618658170996
shaoxiaoyi.sxy@alibaba-inc.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom